Watch · 54/100 · high confidence

SouthState Bank Corp (SSB) — Council Assessment

🟡 WATCH · Score 54/100 · high confidence

A well-run Southeast/Texas regional bank fairly priced at ~1.09x book, but reported earnings are propped up by a wasting purchase-accounting accretion tailwind — quality is real, upside is not.

As of 2026-06-27. 13 lenses weighed in, 5 abstained. Sources: 6 filings, 15 news, 15 discussion, 1 earnings_call.

360 narrative — news & sentiment digest

SouthState Bank Corporation (SSB) — Investment Briefing

Management Commentary (Q4 2025 Earnings Call)

Integration & Strategic Progress Management portrayed successful completion of the Independent Financial Corp acquisition (closed Jan 1, 2025). CEO John Corbett emphasized "well-choreographed integration," regulatory approvals, and systems conversions now "in the rearview mirror." The deal is delivering: excluding merger costs, EPS up 30%+ YoY, and tangible book value per share grew double-digit despite day-one dilution, 11% dividend raise, and 2.4% share repurchases.

Financial Performance (Q4 2025)

EPS: $2.47 (full-year $9.50); Q4 return on tangible common equity ~20%
Net Interest Margin: 386 bps (tax-equivalent), down from Q3 due to lower accretion ($50M vs $83M in Q3). NIM excluding accretion was flat to up 2 bps.
Accretion: ~$260M of remaining loan discount from acquisition still to accrete
Loan/Deposit Growth: 8% annualized in Q4; full-year loan growth 8%
Net Charge-Offs: 9 bps in Q4, 11 bps for full year
Provision: $6.6M; management expects future provisions primarily driven by growth and charge-offs, with "slowing of rotation from PCD to non-PCD"

Capital & Shareholder Returns

Capital Ratios: TCE 8.8%, CET1 11.4%—both healthy
Buyback Activity: Repurchased 2M shares in Q4 (~2% of company) at avg $90.65; board authorized additional 5.5M share authorization
Payout Ratio: 97% in Q4 (dividends + repurchases); management guidance 40–60% sustainable range going forward

Expense & Revenue Outlook

2026 NIE Guidance: +4% (1% for hiring/expansion, ~3% base inflation), from 2025 base of $1.407B
Efficiency Ratio: Below 50% in Q4 and full year
Non-Interest Income: $106M in Q4 (+$7M QoQ), driven by correspondent capital markets strength ($31M, described as "one of our better quarters")
Loan Yields: $6.13% in Q4, down 35 bps, now at new production coupon of 6.06%

Loan Growth & Texas/Colorado Expansion

2026 Guidance: Mid- to upper-single-digit loan growth (previously stated mid to upper)
Pipeline: ~$5B at quarter-end; Q4 production $3.9B
Texas/Colorado: $1B loan pipeline at quarter-end (up from $800M post-conversion); 26 commercial RMs hired in Q4 (17 from conversion); management expects momentum to continue
Markets: Management noted ~$118B of bank deposits in their MSAs will undergo conversion in next ~12 months; recruiting target 10–15% increase in RM headcount (550–600 base) over next 1–2 years, all contained in expense guidance

Deposit Cost & Rate Sensitivity

Cost of Deposits: 182 bps in Q4, down 9 bps QoQ; total cost of funds down 14 bps
NIM Guidance 2026: 380–390 bps (unchanged from prior guidance), assuming 27 bps of loan accretion remaining and stable rate environment; management noted deposit growth will likely fund loan growth
Loan Re-pricing: Large fixed-rate book from acquisition expected to re-price upward over time, offsetting downward pressure from floating-rate portfolio if rates remain stable

Management Tone Confident, detailed, opportunistic: emphasized integration execution, highlighted strong fundamentals vs. near-term market valuation disconnect (justifying aggressive Q4 buyback), and committed to sustained organic growth and RM hiring in 2026.

Recent Developments

Q4 2025 Earnings (Jan 24, 2026): EPS $2.47 (beat $2.30 est.), revenue $686.9M (up 52.5% YoY); full-year EPS $9.50, ROTCE ~20%
Q1 2026 Earnings (Apr 23, 2026): EPS $2.29 (up 160% YoY), revenue $661.7M (down 7% YoY) — mixed signals: EPS beat on acquisition accretion but revenue miss signals normalization
Florida Redomicile (Sep 2025): Company completed redomicile and assumed obligations
Independent Financial Acquisition Closed (Jan 1, 2025): $11B+ deal, expanded into Texas and Colorado

Bull Narrative

Analyst & Management Arguments:

Integration Success: Execution on schedule; accretion and cost synergies tracking; risk profile reduced
Earnings Leverage: Accretion ($260M remaining) should support EPS for next 12–18 months; organic growth (8% loan/deposit) accelerating post-integration
Geographic Expansion: Texas/Colorado markets attracting deposit inflows ($118B in market conversions); RM hiring (26 in Q4, targeting 10–15% growth) primed to capture disruption
Capital Return Flexibility: Strong capital ratios allow sustained 40–60% payout ratio plus opportunistic buybacks; management buying at $90–98 range signals conviction
Fixed-Rate Re-pricing Tailwind: Large acquired loan portfolio set to re-price higher than floating-rate maturing portfolio if rates stabilize
Analyst Ratings (Dec 2025): JPMorgan Overweight, target $115; Barclays Overweight, target $122–125; Raymond James and others flagged SSB among banks benefiting from fewer rate cuts if Fed pauses

Retail Sentiment (forums/alerts): Predominantly bullish; option traders targeting $100+ calls with 55–77% ROI potential; technical traders citing $88.06 support and consolidation above $92.

Bear Narrative

Concerns:

Accretion Cliff Risk: ~$260M remaining accretion will eventually exhaust; NIM ex-accretion was flat to barely positive in Q4, leaving organic NIM vulnerable to further rate cuts or deposit beta squeeze
Deposit Cost Trajectory: Cost of deposits at 182 bps; if Fed cuts further, deposit betas may not decline proportionally, pressuring margin
Revenue Normalization: Q1 2026 revenue missed YoY (-7%), signaling accretion-driven lift may fade; correspondent capital markets strength called "good quarter" but not necessarily sustainable per management tone
Expense Creep: Q4 NIE higher than expected (performance/hiring/marketing up); 2026 guidance +4% may compress margins if loan production/capital markets don't sustain
Execution Risk on RM Hiring: 10–15% RM growth and market capture assume execution and availability; management noted timing is "case-by-case" and timing unpredictable
Valuation: Stock at $93–107 range post-earnings; trading roughly in line with tangible book after accretion support; limited upside if organic growth disappoints or multiple compresses
Loan Yields: New production coupons at 6.06% suggest limited pricing power; potential for yield compression if rates fall further

Skeptic Sources: None explicit in provided material; implied caution in Zacks summary ("mounting expenses could weigh on future performance") and Q1 2026 revenue miss.

Retail Sentiment

Overall: Bullish with tactical hedging

Forums/Social: Positive tone on earnings beats and 28–30% EPS growth YoY; multiple posts targeting $100+ and celebrating Q4 results
Option Activity: Retail buying call spreads and out-of-money calls (Feb $100 calls, Sep $100 calls, Dec $85 calls), betting on continued upside to $100–125 range
Technical Traders: Citing support at $92–93, targeting bounces and breakouts; some citing $88 support as key level
Conviction: Moderate to high, but volume slightly down YoY (per CapitalMonk data May 2026), suggesting some momentum loss post Q1 miss

Caveats

Accretion Dependency: Much of 2025–2026 EPS growth is tied to purchase accounting; organic profitability harder to assess. Management guided 2026 NIM 380–390 bps but this assumes rate stability and deposit funding; no sensitivity tables provided for rate shock scenarios.
Q1 Revenue Miss Not Fully Explained: Q1 2026 revenue down 7% YoY despite loan growth; accretion normalization accounts for some, but underlying NII and fee trends unclear from snippets provided. Subsequent earnings call summaries (not full transcripts) suggest volatility.
RM Hiring/Market Capture Unproven: Texas/Colorado expansion is nascent; $118B bank deposits converting in region is opportunity, but execution on share-of-wallet and retention unclear. Management's 10–15% RM growth target is aspirational; actual hiring pace and success not yet measured.
Margin Guidance Wide: 380–390 bps range is wide and assumes stable rates + no margin beta surprises; any faster rate cuts or deposit competition could challenge lower end.
Retail Trading Activity: Most social/forum discussion is tactical/short-term (weeklies, monthly options); not institutional conviction. Some retail chatter references technical levels that lack fundamental basis.
Limited Color on Credit: Provision expense low ($6.6M), NCOs 9–11 bps; no forward guidance on macro deterioration, concentration risk, or COVID-era loan maturities. Assumes benign credit environment.
Analyst Targets Vary: $115–125 range is broad; no consensus price target in material, and recent Barclays/JPM upgrades may reflect post-Q4 pop, not longer-term outlook.

Bottom Line for Council:
SSB is executing a large, accretive acquisition and generating strong near-term EPS growth. However, much of the upside is front-loaded via purchase accounting. Organic growth is real (8% loans/deposits) and management credibly targeting mid-to-upper single-digit growth in 2026. Capital flexibility is solid, and RM hiring/market expansion provide optionality. Key risks: accretion exhaustion, margin compression from rate cuts or deposit beta, and execution on Texas/Colorado expansion. Valuation appears fair to slightly full at $93–107, with limited catalyst unless organic revenue or loan growth accelerates materially.

Bull case

SSB is a capably managed Sun Belt regional bank with strong capital (CET1 11.4%, TCE 8.8%), pristine credit (NCOs 9-11 bps), efficiency below 50%, and genuine 8% organic loan/deposit growth. The Independent Financial integration was executed cleanly, management is candid and buying back stock at $90-98 (below current price and analyst targets of $115-125), and the Texas/Colorado expansion (26 RM hires, $1B pipeline, $118B in converting deposits) offers a real, trackable roll-out story. The disruption referee (72/100) notes the bank charter is a legal moat AI cannot replicate. At 12.4x P/E and 1.09x book with a fixed-rate loan book set to re-price higher, downside is cushioned by strong capital.

Bear case

The entire long thesis is undercut by earnings quality. Roughly $260M of remaining purchase-accounting accretion is inflating reported EPS ($9.50 FY25); NIM ex-accretion was flat to +2 bps in Q4, and Q1 2026 revenue already fell 7% YoY — the accretion cliff is arriving faster than organic growth can compensate. The forensic short-seller flags a massive accrual gap: net income $799M vs. OCF $301M (166% accrual ratio, <30 cents of FCF per dollar of earnings). The valuation referee's excess-return model shows ROE (8.82%) barely equals cost of equity (~8.5%), implying justified P/B of ~1.06x vs. actual 1.09x — zero margin of safety, with normalized organic ROE likely 6-7% (below CoE) implying sub-book fair value. Stock sits at its 52-week high with bullish consensus already priced in — no fear, no contrarian edge.

Dissent — where the council disagrees

The quality purists split hard: Akre, Fisher, Greenblatt, Greenwald and Terry Smith ALL abstained, deeming banking structurally outside their frameworks — so the 'quality compounder' case has almost no independent support. Among those who did score, there is striking unanimity around ~48-55 (Buffett 58, Munger 52, Mauboussin 52, Graham 55, Klarman 48, Schloss 48, all three risk lenses 52, valuation referee 55, short-seller 52). The lone outlier is the AI/Disruption referee at 72 (Pass), but that lens only answers 'is the franchise a melting ice cube?' — not 'is it a good buy at $101.' Its pass reflects charter durability, NOT valuation or earnings quality, so it should not pull the blended verdict toward buy. The most decision-relevant dissent is the valuation referee + short-seller pairing: both agree the stock is at fair value on inflated earnings, with asymmetric downside if accretion fades before Texas/Colorado ramps.

Key risks

Accretion cliff: ~$260M of purchase-accounting income exhausts over 12-18 months; organic NIM was flat ex-accretion, so normalized EPS could fall to $7-8 from ~$9.50, compressing both earnings and multiple
Q1 2026 revenue already down 7% YoY — accretion normalization is materializing ahead of organic offset
Earnings quality: net income $799M vs. OCF $301M (166% accrual ratio); ROE 8.82% barely covers cost of equity, organic ROE likely 6-7%
Rate sensitivity: NIM guide 380-390 bps assumes rate stability; aggressive Fed cuts would squeeze deposit betas and compress margins
Texas/Colorado expansion is nascent and unproven at scale, with +4% expense guidance adding fixed-cost risk if revenue disappoints
No margin of safety at 52-week high with bullish consensus already priced in; director sold $1.41M in April 2026

Catalysts

2H2026 organic earnings emerging as accretion fades — proof point for whether organic engine sustains EPS
Texas/Colorado RM productivity and loan pipeline conversion
Fed rate path — SSB benefits from fewer cuts (fixed-rate book re-pricing), hurts from aggressive cuts
Continued buyback execution below intrinsic value
Deposit cost trajectory vs. peers as fintech competition intensifies

DCF valuation

Not applicable: FCF-based DCF is not appropriate for Banking — banks/insurers are valued on P/B and ROE, REITs on P/FFO and cap rates.

Short-sell evaluation

🔸 MARGINAL SHORT

The forensic short case is intellectually coherent but not compelling enough to execute. The kill thesis is clean: reported EPS is propped up by ~$260M of wasting purchase-accounting accretion (mechanically declining from $83M in Q3 to $50M in Q4), organic NIM is flat, Q1 2026 revenue already fell 7% YoY, and a de-rate from ~12x to 9-10x as the acquisition premium fades implies 20-25% downside to $75-85. However, this is a well-capitalized (CET1 11.4%), benignly-credited (NCOs 9-11 bps), profitable bank at only 1.09x book with insider buybacks and a real growth story — not a fraud or a broken balance sheet. The valuation is fair, not egregious, so the multiple compression thesis relies on a slow, telegraphed normalization the market already partly sees. Borrow cost, buyback support, low beta (0.70), and the modest 15-25% downside vs. unlimited-upside asymmetry make this a specialist trade, not a fat pitch.

Pros (the short could work)

~$260M accretion cliff will mechanically compress reported EPS as it exhausts over 12-18 months
Q1 2026 revenue -7% YoY confirms accretion normalization is already underway ahead of organic offset
Poor cash conversion: 166% accrual ratio (NI $799M vs OCF $301M), FCF only 29% of net income
ROE 8.82% barely at/below cost of equity; organic ROE likely 6-7%, implying justified P/B below 1.0
97% Q4 payout ratio flagged unsustainable — capital return pulled forward to support the stock
Stock at 52-week high with consensus optimism baked in ($115-125 targets) — limited room for positive surprise

Cons (what kills the short)

Strong capital (CET1 11.4%, TCE 8.8%) and pristine credit (NCOs 9-11 bps) mean no balance-sheet fragility to exploit
Only 1.09x book / 12.4x earnings — already cheap enough that de-rate downside is a modest 15-25%
Management buying back stock at $90-98 and 8% real organic loan/deposit growth support the floor
Low beta (0.70) and defensive Sun Belt franchise limit downside velocity; unlimited-upside asymmetry unfavorable
Fixed-rate loan book re-pricing higher is a genuine forward NIM tailwind if rates stay stable
AI/disruption referee (72) confirms durable charter moat — this is not a secular-decline short

Council scorecard

Lens	School	Stance	Score	Conf
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	72	medium
Warren Buffett	quality	🟡 watch	58	medium
Valuation Referee (Damodaran-style)	referee	🟡 watch	55	medium
Benjamin Graham	value	🟡 watch	55	medium
Ray Dalio	risk	🟡 watch	52	medium
Stanley Druckenmiller	risk	🟡 watch	52	medium
Peter Lynch	growth	🟡 watch	52	medium
Howard Marks	risk	🟡 watch	52	medium
Charlie Munger	quality	🟡 watch	52	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟡 watch	52	medium
Michael Mauboussin	quality	🟡 watch	52	medium
Seth Klarman	value	🟡 watch	48	medium
Walter Schloss	value	🟡 watch	48	medium
Chuck Akre	quality	⚪ abstain	—	high
Philip Fisher	growth	⚪ abstain	—	high
Joel Greenblatt	value	⚪ abstain	—	high
Bruce Greenwald	value	⚪ abstain	—	high
Terry Smith (Fundsmith)	quality	⚪ abstain	—	high

Member reasoning

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

SouthState Bank (SSB) is a traditional community/regional bank. Applying Christensen-style disruption analysis, the core question is: can AI/automation disintermediate or commoditize the specific jobs SSB does for customers — deposit-taking, commercial lending, correspondent banking, and relationship-based financial services in the U.S. Southeast/Texas/Colorado? The honest answer is: partially over 3-10 years, but not existentially. Banks occupy a structurally protected position as licensed deposit-taking institutions backed by FDIC insurance and federal regulation. The charter itself is a legal moat that AI cannot replicate. No LLM can accept deposits, extend federally-regulated credit, or operate a payments clearing system without a bank charter. That said, specific functions within banking are materially exposed. Loan origination decisioning is increasingly AI-automatable; fintechs (Blend, Upstart, etc.) already offer AI-native underwriting. Deposit gathering via digital-first neobanks (Chime, SoFi) continues to erode the branch-as-moat thesis. Correspondent banking and capital markets (a notable revenue line for SSB at ~$31M/quarter) involves execution, matching, and advisory functions that AI could partially commoditize. SSB's business mix skews toward commercial/relationship lending and correspondent banking rather than high-volume consumer origination — this is structurally less exposed to AI-native commoditization than a pure consumer lender. Management's Q4 2025 commentary focused on RM hiring and relationship-driven expansion with no explicit engagement with AI displacement risk, which is typical but not alarming for a bank of this type. On the cost side, AI is a genuine tailwind: banks that deploy AI in back-office operations, credit monitoring, fraud detection, and loan processing can reduce operating costs, and SSB's sub-50% efficiency ratio suggests they are already lean — AI could extend that advantage if adopted. The accretion-driven EPS profile masks underlying organic economics, but the fundamental bank franchise is not a melting ice cube. The strongest disruption scenario for SSB would be: (1) AI-native lenders capturing SMB and commercial loan origination market share in Texas/Colorado before SSB's RM buildout matures; (2) big-tech or fintech deposit platforms pulling core deposits away from community banks, raising funding costs; (3) AI platforms commoditizing correspondent capital markets services. None of these are near-term (2-4 year) existential threats, but the Texas/Colorado expansion is nascent and competing in markets where fintech penetration is higher than SSB's traditional Southeast footprint. Falsifiable signals to watch: deposit cost pressure exceeding peer averages (fintech competition for deposits), take-rate compression in correspondent banking, or loss of commercial loan market share to AI-native lenders in new markets. Confirming signals for durability: continued sub-180 bps deposit costs, stable or rising NIM ex-accretion, and RM-driven loan growth sustained at 8%+ without price concession.

Key points

Bank charter is a legal moat AI cannot replicate — deposit-taking and federally regulated lending require licensing that no AI-native entrant can easily obtain
SSB's commercial/relationship banking and correspondent services model is less exposed to AI commoditization than consumer lending fintechs target
AI is a cost-side tailwind for banks (back-office, fraud, underwriting efficiency); SSB's sub-50% efficiency ratio shows room to compound this advantage
Correspondent banking capital markets (~$31M/quarter) has some AI disintermediation risk but is a niche institutional service with relationship dependencies
Texas/Colorado expansion into higher-fintech-penetration markets increases competitive exposure versus SSB's traditional Southeast franchise
No AI-native entrant can yet replicate the full-stack banking relationship (credit, deposits, treasury, payments) at the SMB/commercial level — SSB's core customer segment

Red flags

Management made no explicit acknowledgment of AI disruption risk in Q4 2025 earnings call — treating AI purely as an operational tool, not a competitive threat to revenue model
Neobank and fintech deposit competition is a real, ongoing pressure on community bank deposit costs — SSB's 182 bps deposit cost needs watching as digital alternatives proliferate
AI-native underwriting (Upstart, Blend, fintech SMB lenders) is capturing market share in exactly the loan categories SSB targets for Texas/Colorado growth
Correspondent banking matching and capital markets advisory functions have partial exposure to AI disintermediation as institutional clients increasingly use algorithmic execution
SSB's RM-dependent growth model could face a secular talent supply constraint if AI tools allow larger banks to serve more clients per RM, intensifying competition for commercial relationships

Warren Buffett — 🟡 watch · 58/100 · medium confidence

SouthState Bank is an understandable, profitable community/regional bank operating in the Southeast U.S. — a business model I can grasp. Banks are within my circle of competence (I've owned Wells Fargo, Bank of America, M&T Bank). SSB has genuine strengths: disciplined management executing a large acquisition, strong capital ratios, low charge-offs, and an efficiency ratio below 50%. However, several quality concerns prevent a confident 'pass.' ROE of 8.8% is materially below my 15% threshold, though ROTCE of ~20% (Q4 2025) is more encouraging and reflects the acquisition's leverage structure. The core problem is that much of the current earnings power is not organic — it is heavily dependent on purchase accounting accretion ($260M remaining from Independent Financial acquisition). When I peel back the accretion, the underlying NIM ex-accretion was barely growing, and Q1 2026 revenue actually declined 7% YoY. This makes it very difficult to assess the true normalized owner earnings power with confidence. Management has been candid (I like that), executed integration on schedule, and bought back stock at $90-98 (below current price) — signaling capital allocation discipline. The balance sheet is conservative: debt-to-equity of 0.006 is negligible, CET1 at 11.4% is solid, and net charge-offs of 9-11 bps are excellent. Price-to-book of 1.09x and P/E of 12.4x on reported earnings are superficially attractive for a quality franchise. But reported earnings include significant non-recurring accretion; normalizing for this, the true earnings power multiple would be higher and the margin of safety thinner. The Texas/Colorado expansion is promising but unproven — I do not pay for optionality I cannot quantify. The 'moat' question is the hardest: SSB is a well-run regional bank in growing Sun Belt markets, but I see limited evidence of structural pricing power beyond geography and relationships. Banks with true moats (low-cost deposit franchises, dominant market positions, switching cost-driven commercial relationships) can sustain 15%+ ROEs without leverage games. I need to see normalized organic ROE well above cost of capital before I commit large capital here.

Key points

ROTCE ~20% in Q4 2025 is strong, but heavily boosted by $260M remaining purchase accounting accretion from Independent Financial deal — normalized profitability is harder to assess
Reported ROE of 8.8% trails my 15% threshold; however, tangible book-based returns are more favorable given goodwill/intangible drag from acquisitions
Efficiency ratio below 50% demonstrates genuine operating discipline — management is executing well on integration
Debt-to-equity of 0.006 and CET1 of 11.4% represent exactly the conservative balance sheet I require; net charge-offs of 9-11 bps suggest sound credit underwriting in current environment
P/E of 12.4x and P/B of 1.09x appear attractive on the surface, but accretion-inflated earnings make the true normalized multiple less compelling; management's own buybacks at $90-98 suggest they see intrinsic value modestly above current price
Management credibility is a positive: candid earnings call commentary, transparent accretion disclosure, disciplined RM hiring within expense guidance, and buybacks at prices below analyst targets
Sun Belt geography (FL, GA, SC, NC, TX, CO) is a genuine long-term demographic tailwind — deposit-rich markets with growth
8% loan and deposit growth annualized in Q4 2025 indicates real organic momentum beneath the accretion story

Red flags

Approximately $260M of remaining purchase accounting accretion will eventually exhaust — the accretion cliff creates a risk that reported EPS growth masks decelerating organic earnings power; Q1 2026 revenue -7% YoY is a warning signal
True organic NIM ex-accretion was flat to +2 bps in Q4 — this is not the pricing power I look for in a bank with a durable moat
ROE of 8.8% on a GAAP basis is well below my required 15%; even granting the intangible/goodwill drag from acquisitions, sustained below-cost-of-equity returns are a structural concern
Texas and Colorado expansion via RM hiring is an unproven growth strategy — I do not pay for expansion plans, only demonstrated results; the $1B pipeline is early-stage
Director David Brooks sold $1.41M in stock in April 2026 near 52-week highs — insider selling at the high end of the range is a mild negative signal
Revenue miss in Q1 2026 (-7% YoY) despite continued loan growth suggests fee income and NII dynamics are more volatile than the bull case implies
No clear articulation of what structural competitive advantage (moat) prevents larger banks or fintechs from competing away SSB's deposit franchise over a 10-year horizon

Valuation Referee (Damodaran-style) — 🟡 watch · 55/100 · medium confidence

The standard FCF-based DCF is flagged not-applicable by the system for banks, and that is correct in the mechanical sense — FCFF DCF misleads for a bank where deposit liabilities are a funding input, not debt to be stripped out. However, Damodaran's approach for banks pivots to an equity DCF (dividend discount or excess return model) anchored on ROE vs. cost of equity, and the fact base provides enough to run that framework. SSB trades at 1.09x tangible book with ROE of 8.82%, a P/E of 12.4x, and reported net income of ~$799M on ~$9.06B of equity. The cost of equity for a Southeast US regional bank with beta ~0.70 is approximately 8.5–9.5% (risk-free ~4.3% + 0.70×6% ERP ≈ 8.5%). At ROE of 8.82%, the bank is barely earning its cost of equity — excess returns are approximately zero or slightly positive. The Gordon Growth dividend-discount formula for a bank: V = Equity × (ROE − g) / (Ke − g). If ROE = 8.82%, Ke = 8.5%, g = 3.5% (nominal GDP-ish growth for a Southeast franchise), then the justified P/B = (0.0882 − 0.035) / (0.085 − 0.035) = 0.0532 / 0.05 = 1.06x book. At $101.37 and 1.09x book, the stock is essentially at fair value — roughly zero margin of safety on base assumptions. The bear case is more concerning: much of 2025 net income is inflated by purchase-accounting accretion (~$260M remaining). Stripping out accretion, organic ROE is likely 6–7%, below cost of equity, implying the stock would trade below book on pure organic fundamentals. The bull case requires accretion to continue bridging while Texas/Colorado expansion delivers sustained above-cost-of-equity organic returns — possible but unproven and time-limited. The 160% YoY Q1 2026 EPS jump is almost entirely an accretion artifact; underlying revenue fell 7% YoY. On the implied-expectations test: the market at 12.4x earnings and 1.09x book is pricing in modest but positive excess returns persisting. That is not obviously wrong — SSB is a well-run Southeast bank with strong capital (CET1 11.4%), but the expectations require the Texas/Colorado buildout to succeed and the fixed-rate loan book to re-price upward before accretion exhausts. No margin of safety exists for the optimistic scenario; the bear scenario (organic ROE < Ke, accretion cliff) yields a justified P/B below 1.0, implying ~8–10% downside. The P/FCF of 43x is misleading for a bank and should be disregarded. The watch verdict reflects: price ≈ fair value under base assumptions, with asymmetric downside if accretion fades faster or organic returns disappoint, and limited upside unless the expansion story proves out.

Key points

Excess-return bank valuation: ROE (8.82%) ≈ cost of equity (~8.5%), implying justified P/B of ~1.06x vs. actual 1.09x — effectively zero margin of safety
Accretion dependency is the central valuation risk: ~$260M remaining purchase-accounting accretion inflates reported earnings; organic ROE likely 6–7%, below cost of equity
P/E of 12.4x and 1.09x book are fair-value multiples for a bank with ROE barely at cost of equity — not a bargain, not a bubble
Bull case requires Texas/Colorado RM expansion to generate above-WACC returns before accretion exhausts, a 12–18 month execution window that is unproven
Capital position is solid (CET1 11.4%, TCE 8.8%), which limits downside risk and supports the current multiple — but does not create upside without ROE improvement
Q1 2026 revenue down 7% YoY with EPS up 160% is a classic accretion-driven distortion; the two numbers cannot both be trusted as signals of business health

Red flags

No margin of safety: price sits at ~fair value under base ROE/cost-of-equity assumptions; needs optimistic scenario to generate alpha
Accretion cliff: organic NIM flat ex-accretion in Q4 2025; if accretion exhausts before Texas/Colorado volumes ramp, reported earnings will fall sharply
Story-number tension: management narrative emphasizes 8% organic loan/deposit growth and 20% ROTCE, but ROTCE is accretion-enhanced; tangible organic ROE is materially lower
Director sold $1.41M in stock (Apr 2026) while price was near 52-week highs — a mild but notable negative insider signal
Revenue miss in Q1 2026 (-7% YoY) despite EPS beat suggests top-line normalization is already underway, ahead of accretion exhaustion

Benjamin Graham — 🟡 watch · 55/100 · medium confidence

SouthState Bank Corporation presents a mixed picture through Graham's lens. On the positive side, the bank trades at 1.09x tangible book value — modest by historical banking standards — and carries a trailing P/E of approximately 12.4x, which sits below Graham's 15x defensive ceiling. The product of P/E × P/B is roughly 13.5, comfortably under the 22.5 threshold. ROE of 8.8% is modest but positive, and the bank appears to have uninterrupted dividend payments with an 11% dividend raise announced. The balance sheet shows total equity of $9.06B against total assets of $67.2B — standard banking leverage, not alarming by sector norms. Net charge-offs of 9-11 bps are very low, suggesting benign credit quality currently. However, several Graham criteria cannot be cleanly applied or are concerning. Banks are structurally exempt from the current ratio and working-capital tests (assets and liabilities are fundamentally different from industrial balance sheets), so those filters must be set aside. More troubling from a Graham standpoint is the earnings quality question: a substantial portion of 2025 EPS ($9.50 full-year) is driven by purchase accounting accretion from the Independent Financial acquisition (~$260M remaining discount to accrete), not organic earning power. Graham demanded demonstrated, repeatable earnings — accretion-inflated figures are one-time in nature and will fade. The Q1 2026 revenue miss (-7% YoY) and flat core NIM suggest underlying organic profitability is weaker than headline numbers imply. True normalized earnings power is materially harder to assess. The long-term debt figure reported ($55M) appears stale (2016 period), and cash/equivalents data is similarly dated (2017), limiting confidence in balance-sheet precision. Operating cash flow of $301M against net income of $799M is a notable gap — suggesting large non-cash accruals, which a conservative analyst must treat with caution. Director selling ($1.41M) is a mild negative signal. The stock is at its 52-week high per the price block (though fundamentals show a 52w range of $84.48-$108.46), suggesting Mr. Market is not offering a pessimistic price. At ~1.09x book and 12.4x earnings the valuation is not egregiously high, but there is no meaningful margin of safety — Graham required a discount, not merely fair pricing. The accretion cliff risk means forward normalized P/E is likely higher than the reported 12.4x once purchase accounting fades.

Key points

P/E of 12.4x is below Graham's 15x defensive ceiling; P/E × P/B of ~13.5 is under the 22.5 threshold — passes the combined multiple test
Price-to-book of 1.09x is modest; not a deep asset discount but not egregiously expensive for a performing bank
Trailing net income $799M, but significant portion is accretion income from Independent Financial acquisition — normalized organic earnings power is lower and harder to verify
Net charge-offs 9-11 bps and provision of $6.6M signal benign credit environment currently
Capital ratios solid: TCE 8.8%, CET1 11.4%; bank appears adequately capitalized
Dividend raised 11% in 2025; history of payments signals some shareholder discipline
Traditional Graham balance-sheet tests (current ratio ≥2, LTD vs working capital) are structurally inapplicable to banks

Red flags

No margin of safety: stock near 52-week high with P/B only modestly below 1x; Graham demands a discount to conservatively estimated intrinsic value, not mere fairness
Earnings quality concern: ~$260M of remaining purchase accounting accretion inflates EPS; normalized earnings yield is materially lower than 12.4x P/E implies
Operating cash flow ($301M) is less than 40% of reported net income ($799M) — large gap raises questions about earnings substance that Graham would scrutinize carefully
Key balance-sheet data points appear stale (cash equivalents from 2017, long-term debt from 2016) — fact base insufficient for rigorous Graham balance-sheet analysis
Q1 2026 revenue down 7% YoY signals potential normalization; accretion exhaustion risk is real and earnings stability over a forward decade cannot be confidently assumed
Director selling $1.41M in April 2026 is a modest negative insider signal
Texas/Colorado expansion and RM hiring are growth narratives; Graham values demonstrated results, not aspirational market capture

Ray Dalio — 🟡 watch · 52/100 · medium confidence

SouthState Bank (SSB) is a rate-sensitive regional bank — precisely the type of financial institution where the Dalio macro lens is most relevant. Banks are inherently leveraged balance sheets operating across debt-cycle and rate regimes. SSB presents a mixed picture: it has genuine NIM tailwinds in a higher-rate, stable-growth environment (one regime), but is meaningfully exposed to stagflation (credit losses + margin pressure from deposit competition) and deflationary deleveraging (rising defaults, NIM compression, credit contraction). The balance sheet is not fragile by banking standards — TCE 8.8%, CET1 11.4%, minimal long-term debt ($55M reported), low D/E of 0.006 — but the bank is inherently a levered entity with $67B in assets against $9B in equity (implying roughly 7.4x leverage). The Independent Financial Corp acquisition adds integration risk and creates accretion dependency that masks organic earnings quality. ROE of 8.8% is decent but not exceptional for a leveraged financial. The bank operates in a single geography (Southeast US / Texas / Colorado), USD-only, with high correlation to the US credit cycle and domestic growth — no meaningful geographic or FX diversification. The accretion cliff (only $260M remaining from acquisition) means 2026-2027 earnings quality depends heavily on organic NIM, which management guided 380-390bps but with acknowledged sensitivity to rate cuts and deposit beta. In a stagflation scenario (rising inflation, slowing growth), credit losses would rise while deposit costs remain sticky, compressing NIM from both sides — the worst box for a regional bank. In a deflationary bust, loan demand collapses, credit losses spike, and the acquisition premium could be impaired. SSB only clearly wins in the rising growth / stable-to-moderately-rising rates box — single-regime dependence is a core Dalio red flag. Positives: low explicit leverage in terms of stated long-term debt, reasonable capital ratios, below-50% efficiency ratio, modest beta (0.70), and share buybacks at $90 signal some balance sheet confidence. Raymond James noted SSB among rate-stable beneficiaries, consistent with its fixed-rate book re-pricing upward. But the overall risk/reward from a regime-robustness standpoint is limited.

Key points

Balance sheet leverage is inherent to banking: $67B assets / $9B equity = ~7.4x, acceptable for a well-capitalized regional bank (CET1 11.4%, TCE 8.8%)
NIM of 386bps (tax-equivalent) with $260M remaining accretion supports near-term earnings, but organic NIM ex-accretion is flat — regime-dependent
Fixed-rate acquired loan book provides re-pricing tailwind in stable/higher rate environment — one positive regime factor
Low reported long-term debt ($55M) and D/E 0.006 — minimal explicit refinancing wall risk; funded primarily via deposits (natural bank liability)
Cost of deposits 182bps falling 9bps QoQ — deposit beta manageable so far, but sensitive to rate trajectory
8% annualized loan and deposit growth in Q4 2025 — organic growth is real but concentrated in US Southeast, Texas, Colorado — no geographic or FX diversification
Beta 0.70 and P/B 1.09 suggest moderate equity market correlation; bank stocks tend to cluster in drawdowns — not a diversifying asset class
Analyst consensus Overweight ($115-125 price targets) prices in stable-rate, continued growth scenario — limited cushion for regime shift

Red flags

Single-regime dependence: SSB's earnings model works best in rising/stable growth + stable/rising rates; both stagflation (deposit cost sticky, credit losses rise) and deflationary deleveraging (loan demand collapse, NCO spike) would materially impair earnings
Accretion cliff: ~$260M remaining purchase accounting accretion is a wasting asset; organic NIM was flat ex-accretion in Q4 2025 — earnings quality opaque and regime-masking
Geographic concentration: 100% domestic USD exposure in Southeast US / Texas / Colorado — no diversification against US-specific credit cycle or dollar debasement scenarios
Pro-cyclical loan growth: 8% growth partly reflects post-acquisition momentum and regional economic expansion; if US enters credit contraction, loan demand and asset quality would deteriorate simultaneously
No inflation pass-through in the traditional sense: banks cannot simply raise loan rates on existing fixed-rate books; deposit costs may rise faster than loan yields in inflationary environment with Fed tightening
Q1 2026 revenue missed YoY by 7% despite loan growth — signals accretion normalization underway faster than expected; masks underlying organic revenue trajectory
Director insider selling ($1.41M in April 2026) while buybacks occur — mixed insider signal
Texas/Colorado expansion is nascent and unproven; $118B deposit conversion opportunity is real but execution-dependent; RM hiring (10-15% growth target) adds expense risk

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

SSB presents a genuine earnings inflection story post-Independent Financial acquisition, but the setup fails several of my core criteria for high-conviction sizing. The forward earnings narrative is partially compelling — Q4 2025 EPS up 28-31% YoY, ROTCE ~20%, strong loan/deposit growth of 8%, and $260M of remaining purchase accounting accretion providing a runway through 2026. Management is executing and the Texas/Colorado expansion is optionality worth tracking. However, the critical flaw from my lens: the EPS growth is substantially accretion-driven, not organic earnings acceleration. The second derivative of organic NIM was flat to barely +2 bps ex-accretion in Q4 — that is NOT an inflecting earnings machine, that is a purchase-accounting harvest winding down. Q1 2026 revenue missed by -7% YoY, which is exactly the deceleration pattern I fear. The Fed/liquidity picture is mixed at best — rate cuts expected but now pushed out, and the Raymond James note specifically flags SSB as a bank that benefits from FEWER cuts, meaning the Fed tailwind is actually counterintuitive here and the macro setup is ambiguous rather than clean. On tape: stock is at its 52-week high of $101.37 with strong recent momentum, which is constructive and the one factor arguing for engagement. But price-to-book of 1.09x and analyst targets at $115-122 suggest only 14-20% upside with a muddled organic growth story — insufficient asymmetry for a concentrated Druckenmiller-style bet. The thesis lacks a single clean, high-conviction catalyst: accretion will diminish, organic NIM is flat, RM hiring in Texas/Colorado is multi-year with uncertain timing, and the Fed regime is unclear. I'd watch for the accretion cliff to reveal the true organic earnings power — if 2026 organic NIM expands and loan growth sustains 8%+ without the acquisition crutch, the thesis could crystallize into a real buy. Not there yet.

Key points

Q4 2025 EPS $2.47 beat estimates; full-year EPS $9.50 with ROTCE ~20% — strong headline numbers
$260M remaining purchase accounting accretion provides earnings runway through 2026 but is a finite, known tailwind not organic acceleration
8% annualized loan and deposit growth is genuine organic momentum worth crediting
Texas/Colorado expansion via 26 RM hires and $1B pipeline is optionality but unproven and multi-year
Stock at 52-week high ($101.37) confirms price confirmation criterion — tape is not disagreeing
Barclays Overweight $122, JPMorgan Overweight $115 — institutional sponsorship is constructive but not yet a crowding risk
Capital ratios solid (CET1 11.4%, TCE 8.8%) with aggressive buybacks at $90-98 — management conviction signal

Red flags

Organic NIM ex-accretion was flat to +2 bps in Q4 — no real earnings acceleration in the underlying business, just acquisition harvest
Q1 2026 revenue down 7% YoY — decelerating top line is the exact second-derivative warning I watch for
Accretion cliff is a known, unavoidable headwind: $260M remaining will exhaust over 12-18 months, compressing reported EPS unless organic replaces it
Fed/liquidity tailwind is ambiguous: SSB benefits from FEWER rate cuts per Raymond James, making it a rate-hike hedge not a liquidity beneficiary — this complicates my macro framing
Asymmetry is limited: P/B 1.09x, analyst targets $115-122 imply 14-20% upside vs. meaningful downside if accretion-driven EPS disappoints
No single clean catalyst with defined timing — RM hiring, Texas expansion, and accretion normalization are all multi-quarter, multi-variable stories
Director David Brooks sold $1.41M in stock in April 2026 — insider selling at current levels reduces conviction

Peter Lynch — 🟡 watch · 52/100 · medium confidence

SouthState Bank Corp is best categorized as a stalwart/turnaround hybrid — a mid-size regional bank executing a large acquisition (Independent Financial, ~$11B deal closed Jan 1, 2025) with purchase-accounting accretion masking the true organic earnings picture. The Lynch framework applies, but with important caveats specific to banking. The headline EPS story looks compelling: Q4 2025 EPS $2.47 (28-31% YoY), full-year 2025 EPS $9.50, Q1 2026 EPS $2.29 (up 160% YoY on low base). At $101.37 and ~$9.50 annualized EPS, the P/E is approximately 10.7x. If I take the 2025 EPS growth rate at face value (~28-30%), the PEG looks outstanding — around 0.35-0.40. But this is the trap: the bulk of that EPS growth is purchase-accounting accretion ($260M remaining loan discount, ~$83M hitting Q3 2025 alone, normalizing to ~$27M per quarter per 2026 guidance). This is a one-time, non-repeatable earnings driver — exactly the kind of 'story that doesn't add up' when you strip it out. Organic NIM ex-accretion was flat to up only 2 bps in Q4, which tells me the underlying bank is not growing earnings at anywhere near 28%. Adjusting for accretion normalization, sustainable EPS growth is probably mid-to-upper single digits (8% loan growth, 4% expense growth, modest fee income). That puts the true organic PEG at roughly 1.0-1.3x — fair at best for a stalwart, not exciting for a Lynch fast grower. The balance sheet is actually decent for a bank: debt-to-equity 0.006 (minimal long-term debt outside of deposits), CET1 11.4%, TCE 8.8%. Price-to-book is 1.09x, which is genuinely cheap. ROE at 8.82% is sub-par but poised to improve as accretion and synergies flow through. The buyback at $90-98 is a positive signal — management put their own authorization where their mouth is. The Texas/Colorado expansion via RM hiring is a Lynch-style 'roll-out' story I can follow: 26 commercial RMs hired in Q4, $1B pipeline, targeting $118B of deposits undergoing market conversion. That's a real, trackable expansion narrative. However, Q1 2026 revenue was down 7% YoY, signaling accretion cliff risk is materializing faster than bulls hope. Analyst coverage is moderate (JPM and Barclays both Overweight at $115-125), so there's some institutional support but not crowded. The business is easy to explain (Southeast/Sun Belt regional bank, acquired a Texas bank, growing commercial relationships) — passes the Lynch understandability test. The core concern: this is NOT a 20-25% organic fast grower. It's a stalwart with a post-acquisition accretion sugar high that will normalize. For Lynch purposes, I'd want to see 2-3 quarters of organic loan/deposit/NII growth demonstrating the Texas/Colorado roll-out is real before paying up. At ~10.7x P/E and 1.09x book, the downside is limited, but the upside catalyst (accretion + organic acceleration) is uncertain. A watch rather than a pass.

Key points

P/E of ~10.7x on $9.50 FY2025 EPS looks cheap, but EPS growth is heavily distorted by ~$260M remaining purchase-accounting accretion that will exhaust in 12-18 months
True organic NIM was flat to +2 bps ex-accretion in Q4 2025; Q1 2026 revenue down 7% YoY signals accretion normalization is the near-term headwind
Lynch 'roll-out' story is identifiable: 26 commercial RMs hired in Q4, $1B Texas/Colorado pipeline, $118B deposit market conversions — real and trackable
Price-to-book at 1.09x with CET1 11.4% provides genuine downside protection; management buyback at $90-98 is a credibility signal
8% annualized loan and deposit growth is solid organic foundation; mid-to-upper single-digit guidance for 2026 is believable
Balance sheet is clean for a bank: D/E 0.006, strong capital ratios, no near-term debt maturities visible

Red flags

EPS growth rate is artificially inflated by non-recurring purchase-accounting accretion — strips the PEG calculation of meaning; true organic PEG likely 1.0-1.3x, not 0.35x
Q1 2026 revenue miss (-7% YoY) is an early warning that accretion cliff is arriving; organic revenue growth not yet proven post-integration
'Diworsification' risk: $11B acquisition into new geographies (Texas, Colorado) introduces execution risk that management has not yet fully demonstrated at scale
ROE at 8.82% is below cost of equity for a bank — not yet generating economic profit on a sustainable basis
Expense guidance +4% in 2026 with RM hiring creates margin pressure if loan production or fee income disappoints
Correspondent capital markets revenue called 'one of our better quarters' by management — not a reliable or repeatable earnings driver to model growth on

Howard Marks — 🟡 watch · 52/100 · medium confidence

SouthState Bank (SSB) is a well-run regional bank that completed a transformative acquisition (Independent Financial, Jan 2025) and is executing capably. However, assessing it through a Marks risk lens, the critical question is: what is priced in, and where is the margin of safety? At ~$101 with a P/B of 1.09x tangible book and P/E of 12.4x, the valuation is modest by historical bank standards but not clearly cheap. The stock is trading essentially at its 52-week high, implying the market has already absorbed the good news — EPS up 30%+, strong ROTCE ~20%, successful integration narrative. The bull case (accretion, RM hiring, Texas/Colorado expansion, analyst upgrades to $115–125) is widely known and already partially capitalized. This is NOT a situation of fear, forced selling, or revulsion — the sentiment is broadly bullish (JPMorgan OW $115, Barclays OW $122, retail option buyers targeting $100+ calls). The pendulum is NOT at fear; it's somewhere between neutral and mild optimism. That said, the capital structure is genuinely sound: CET1 11.4%, TCE 8.8%, debt/equity 0.006, and NCOs at only 9–11 bps — this is not a fragile balance sheet. The key Marks-framework concern is the earnings quality: ~$260M of remaining purchase accounting accretion is front-loading EPS, masking true organic NIM which was flat ex-accretion. Q1 2026 revenue actually missed YoY (-7%), suggesting normalization is already visible. Once accretion exhausts over 12–18 months, the bar for organic earnings to sustain the multiple rises sharply. The 'flawless execution' narrative (RM hiring, Texas expansion capturing $118B in converting deposits) is aspirational and unproven at scale. Expense growth guided +4% in 2026 with uncertain revenue offset. This is not a situation of obvious cheapness — it's a quality bank at a fair price with a modestly favorable but consensus-recognized growth story. The asymmetry is limited: downside if accretion fades and organic growth disappoints could compress to 0.85–0.90x tangible book (~$78–83/share, roughly 18–23% downside); upside to analyst targets of $115–122 is 14–20%. That's not the skew Marks demands. I score this a watch — not a panicked, out-of-favor name offering a fat pitch, but not grotesquely overpriced either.

Key points

P/B of 1.09x and P/E of 12.4x are not demanding multiples for a bank with 20% ROTCE, but stock is at 52-week high with bullish analyst consensus already published — optimism is substantially priced in
Capital structure is genuinely robust: CET1 11.4%, TCE 8.8%, near-zero long-term debt, NCOs 9–11 bps — survivability in a downturn is solid, which is the key Marks safety criterion
~$260M remaining purchase accounting accretion is the primary EPS engine; NIM ex-accretion was flat in Q4 2025, meaning organic earnings power is harder to assess and the 'real' earnings yield is lower than headline P/E implies
Sentiment is clearly bullish (JPM OW $115, Barclays OW $122, retail call buying, Q4 EPS beat celebration) — the pendulum is not at fear, which reduces contrarian edge
8% organic loan/deposit growth and 26 RM hires in Q4 suggest real underlying franchise strength — this is not a deteriorating business
Texas/Colorado expansion into disrupted markets ($118B in converting deposits) is a genuine medium-term catalyst, but execution is aspirational and unproven at scale
Q1 2026 revenue miss (-7% YoY) is an early warning that accretion normalization is already visible in reported results

Red flags

Optimism substantially priced in — stock at 52-week high with consensus analyst upgrades at $115–125 already published; no 'fear in the price' for a contrarian entry
Accretion cliff risk: $260M remaining accretion will exhaust; organic NIM was flat ex-accretion in Q4 2025; if rates cut further or deposit betas don't cooperate, true earnings power could disappoint materially
Q1 2026 revenue down 7% YoY despite positive headline EPS — signals that accretion-driven optics are masking underlying revenue normalization
Expense guidance +4% in 2026 with uncertain revenue coverage; correspondent capital markets called a 'good quarter' (implying potential non-recurrence)
Risk/reward asymmetry is limited: downside to 0.85–0.90x tangible book (~$78–83) vs. analyst upside to $115–122 is roughly symmetric — not the fat asymmetric skew Marks demands
Crowded consensus: multiple bulge-bracket upgrades, retail option buyers, and management buyback narrative all point the same direction; no variant view with informational edge available here

Charlie Munger — 🟡 watch · 52/100 · medium confidence

SouthState Bank is a real, understandable regional banking business — a community bank that lends money, takes deposits, and earns a spread. That sits within my circle of competence at a basic level. The business is not a black box. However, banking is a peculiar animal: it is inherently leveraged, heavily regulated, and fundamentally dependent on management's judgment about credit quality in ways that are hard for an outside investor to verify until a cycle turns ugly. I can assess it, but with humility about what I cannot see. On quality metrics, the picture is genuinely mixed. ROE of 8.8% is mediocre — well below my 15%+ threshold for a great business. ROTCE of roughly 20% in Q4 2025 looks more attractive, but this is heavily inflated by purchase accounting accretion from the Independent Financial acquisition; ex-accretion the underlying franchise earns considerably less. The moat question is the central one: regional banks have modest switching costs on the deposit side and face commodity-like pricing on most loan products. SouthState has geographic concentration in high-growth Southeast markets (now expanding into Texas/Colorado), which is a tailwind, not a moat. Management appears capable and candid — the Q4 2025 earnings call tone was detailed and owner-minded, the aggressive buyback at $90-98 signals real conviction, and capital ratios (CET1 11.4%, TCE 8.8%) are healthy. The 11% dividend raise and disciplined payout guidance (40-60%) suggest rational capital allocation. But the Independent Financial acquisition ($11B+ deal) was substantial M&A that introduced meaningful integration risk, goodwill, and purchase accounting complexity that obscures the true earning power of the underlying bank. The accretion dependency is the biggest quality concern: roughly $260M of remaining loan discount will juice reported EPS for 12-18 more months, then fade. Q1 2026 already showed revenue down 7% YoY — a preview of the normalization headwind. At 12.4x earnings and 1.09x book, the price is not expensive for a bank of this quality, but it is not obviously cheap either. The price-to-FCF at 43x is misleading for a bank (operating cash flow at $300M versus net income at $799M is an artifact of bank accounting, not a cash conversion problem per se, but it illustrates why FCF metrics are unreliable here). On inversion — what could permanently impair capital? A credit cycle deterioration in the Southeast/Texas markets with concentrated CRE exposure, a deposit flight driven by fintech disintermediation, or management making another large ill-timed acquisition. None is probable in the near term, but none is implausible over a five-year horizon. Bottom line: this is a decent-to-good regional bank, not a great franchise. The moat is thin, the quality is real but not exceptional, the current earnings are temporarily inflated by acquisition accounting, and the price is fair but not a bargain for a Munger-style quality compounder. I would watch, not buy.

Key points

ROE of 8.8% is below my 15%+ quality threshold; ROTCE of ~20% is inflated by acquisition accretion and will normalize
~$260M remaining purchase accounting accretion is a temporary EPS tailwind — Q1 2026 revenue -7% YoY foreshadows normalization
CET1 11.4% and TCE 8.8% are solid capital ratios; management buyback at $90-98 and 40-60% payout guidance show owner-minded discipline
Geographic footprint in Southeast growth markets plus Texas/Colorado expansion provides real organic opportunity but is not a moat
P/B of 1.09x and P/E of 12.4x are fair, not cheap, for a bank with temporary accretion support — limited margin of safety
Management tone in Q4 earnings call was candid and detailed; Corbett's aggressive buyback signals conviction
Regional banking moat (switching costs, local brand) is modest and faces competitive pressure from larger banks and fintech

Red flags

Accretion cliff: ex-accretion NIM was flat; organic NIM vulnerable once $260M discount accretes through
Q1 2026 revenue missed YoY by 7% — early sign of accretion fade, and underlying organic revenue trend unclear
Large M&A (Independent Financial) introduces goodwill, integration risk, and opaque purchase accounting that obscures true earning power
ROE of 8.8% — a mediocre return business dressed up by leverage and timing; not a high-quality compounder by my standard
Director selling $1.41M in stock (David Brooks, April 2026) is a modest negative signal at current price levels
Texas/Colorado expansion is nascent with unproven execution — $1B pipeline is promising but not yet demonstrated revenue
Expense creep: Q4 NIE higher than expected; 2026 guide +4% may compress margins if revenue normalizes

Forensic Short-Seller (Chanos/Einhorn-style) — 🟡 watch · 52/100 · medium confidence

SouthState Bank (SSB) is a serial acquirer that closed a large ($11B+ Independent Financial Corp) deal on Jan 1, 2025, making it a legitimate forensic target. The core earnings-vs-cash divergence test is the primary tool here, and it raises yellow flags: net income of $798.7M vs operating cash flow of only $300.8M for FY2025 — a gap of ~$498M, meaning reported earnings exceeded OCF by ~66%. FCF (OCF minus capex) is a mere $230.6M against $798.7M in net income — a ratio of roughly 0.29x, i.e., less than 30 cents of free cash for every dollar of reported earnings. For a bank, this is partly structural (banks are not valued on FCF), but the magnitude of the earnings-vs-OCF gap warrants scrutiny. The primary driver appears to be purchase accounting accretion — management itself disclosed ~$260M of remaining loan discount accreting into income, and Q3 2025 accretion was $83M vs Q4's $50M. This is classic acquisition-driven earnings inflation: non-cash income that boosts GAAP net income without corresponding cash generation. The NIM ex-accretion was flat to +2bps in Q4, revealing thin organic margin generation. Q1 2026 revenue fell 7% YoY despite loan growth, confirming accretion normalization is underway. On buybacks: management repurchased 2M shares in Q4 at avg $90.65 while also awarding stock compensation; the net dilution effect is unclear from available data but the payout ratio hit 97% in Q4 (dividends + repurchases), which is unsustainable and was explicitly flagged by management as a one-time. On insider activity: a director (David Brooks) sold $1.41M in stock in April 2026, and another director received shares in lieu of cash — modest signals but worth noting. Governance appears conventional. Debt is minimal (long-term debt $55.4M reported, though this figure appears stale/incomplete for a $67B asset bank — deposit funding dominates). CET1 at 11.4% is healthy. Credit quality appears benign (NCOs 9-11bps) but forward macro risk is unaddressed. The kill thesis would be: accretion exhausts faster than organic NIM expands, deposit costs remain sticky as rates potentially cut further, expense creep from RM hiring accelerates, and the stock de-rates from ~12x P/E to 9-10x as the acquisition premium fades — implying 20-25% downside to $75-85. The bear case is real but not imminent; this is a 'watch' not a 'short' given solid capital, benign credit, and management execution so far.

Key points

Massive earnings-vs-OCF divergence: net income $798.7M vs OCF $300.8M (FY2025), FCF only $230.6M — less than 30 cents of cash per dollar of reported earnings
~$260M of remaining purchase accounting loan discount accreting into income — non-cash earnings inflation from acquisition that will exhaust over 12-18 months
NIM ex-accretion flat to +2bps in Q4 2025; Q1 2026 revenue down 7% YoY confirms accretion normalization is underway and organic profitability is thinner than headline numbers suggest
Serial acquirer risk: rapid growth via M&A (IFB acquisition $11B+) masks organic business quality; management compensation and reporting complexity increase
Q4 2025 payout ratio 97% (dividends + buybacks) — management explicitly flagged as unsustainable, suggesting capital return was pulled forward to support stock price post-acquisition
Barclays and JPM Overweight ratings with targets $115-125 vs current $101 — analyst optimism baked in, limited upside catalyst if organic growth disappoints
Director David Brooks sold $1.41M in April 2026 — minor but directionally negative insider signal at current price levels
Long-term debt figure ($55.4M) appears stale/incomplete in the data; actual funding structure for a $67B bank needs deeper scrutiny of FHLB advances and other wholesale funding

Red flags

Net income ($798.7M) exceeds OCF ($300.8M) by $498M — a 166% accrual ratio, the single biggest forensic concern; even adjusting for banking sector norms this gap is large and driven by non-cash acquisition accretion
FCF of $230.6M represents only 28.9% of reported net income — earnings quality is poor by cash conversion standard
Purchase accounting accretion is the primary earnings driver and is mechanically declining: $83M in Q3 2025 fell to $50M in Q4 2025; when the $260M pool exhausts, reported EPS will face a structural step-down
Q1 2026 revenue miss (-7% YoY) is the first observable evidence of accretion cliff — organic revenue growth is not yet covering the fade
97% payout ratio in Q4 signals management used leverage of buybacks to prop stock; unsustainable without continued strong earnings
Expense guidance +4% in 2026 on top of acquisition integration costs; if RM hiring targets (10-15% headcount growth) miss, efficiency ratio deteriorates
Stale/incomplete balance sheet data in fact base (long-term debt period listed as 2016, cash period 2017) — signals data gaps that make full forensic analysis of liability structure impossible
No credit sensitivity analysis provided by management for macro deterioration scenarios; 9-11bps NCOs assume benign environment that may not persist in Texas/Colorado expansion markets

Michael Mauboussin — 🟡 watch · 52/100 · medium confidence

SouthState Bank (SSB) is a legitimate candidate for quality/expectations analysis, though the banking lens requires adapting ROIC-above-WACC to ROE-above-cost-of-equity. The firm generates ROE of 8.82% on reported book, which is likely below its cost of equity (~9-10% for a regional bank), making value creation marginal at best on reported figures. However, this is heavily distorted by acquisition goodwill/intangibles and purchase accounting: ROTCE was ~20% in Q4 2025 and the management narrative describes a 30%+ EPS growth trajectory driven partly by $260M remaining loan discount accretion. The core question for expectations investing is: how much of the embedded price assumes (1) accretion-driven near-term EPS (~$9-10 annualized) versus (2) durable organic ROTCE in the high-teens? At 1.09x tangible book and 12.4x trailing P/E, the market is pricing something between 'ordinary regional bank' and 'modestly superior franchise' — which is about right if organic ROTCE normalizes to 14-16% post-accretion, but too generous if it reverts to the 10-12% range many acquirers experience. The moat analysis is the hardest part: SSB has switching costs (commercial banking relationships, treasury management, correspondent banking) and modest scale advantages in its Southeast core markets, but no network effects and no pricing power beyond peer. The Texas/Colorado expansion is aspirational optionality, not a demonstrated moat extension. The accretion cliff is the single largest expectations risk — when the $260M runs off, consensus may discover the organic earnings power is $7-8/share, not $9-10, compressing the multiple. Against that, the 8% loan/deposit growth and 550+ RM base with planned 10-15% headcount growth are real and concrete positive signals. Capital allocation discipline is evident (buybacks at $90-98, well below $115-125 analyst targets, suggesting management believes the stock is cheap; payout ratio guidance 40-60% is prudent). Insider selling by director David Brooks at $1.41M is a minor red flag worth noting. The distribution of outcomes has a fat left tail if the Fed cuts rates aggressively (deposit beta squeeze, margin compression below 380 bps NIM), a plausible base of 14-16% organic ROTCE supporting ~$100-110 fair value, and a right tail if Texas/Colorado hires deliver outsized loan growth and market share capture. The price at $101 is roughly at the base expectation — no meaningful margin of safety on quality-adjusted basis, but not egregiously overvalued either.

Key points

ROTCE ~20% in Q4 2025 is impressive but approximately half is purchase accounting accretion ($260M remaining); organic ROTCE likely 14-16% post-accretion, still above cost of equity but the spread is narrow
P/B of 1.09x and P/E of 12.4x imply market is pricing in a modest but not exceptional franchise — the embedded expectations appear roughly consistent with a 14-16% sustainable ROTCE, leaving limited upside
Moat sources are real but narrow: commercial banking switching costs (treasury/cash management, embedded relationships), correspondent banking scale (hard to replicate quickly), and Southeast geographic density — but no network effects and limited pricing power
Capital allocation discipline is above average: aggressive buyback at $90.65 avg (management signaling intrinsic value well above market price), 11% dividend raise, prudent 40-60% payout target, and no signs of empire-building beyond the now-integrated Independent Financial deal
8% annualized loan/deposit growth and $5B pipeline with 26 new RMs hired in Q4 represent concrete organic momentum, not just acquisition-driven noise
Revenue miss in Q1 2026 (-7% YoY) with EPS beat (160% YoY) signals the accretion-vs-organic divergence is already visible to the market — expectations for 2H2026 will test whether the organic engine can sustain EPS as accretion fades
Outside view: regional bank acquirers historically see ROTCE reversion to 12-14% range within 3-5 years post-acquisition; SSB must demonstrate Texas/Colorado and organic RM productivity to beat the base rate

Red flags

Accretion cliff: $260M remaining purchase accounting discount accretable income will exhaust over 12-24 months; without it, normalized EPS likely $7-8 vs current ~$9-10 run rate — the expectations embedded in $101 may not be fully discounting this
ROE of 8.82% on reported book is below cost of equity, reflecting goodwill/intangibles from acquisition; investors relying on this metric alone would conclude no value creation — quality of earnings requires careful adjustment
Director David Brooks sold $1.41M in stock at current prices while management simultaneously cites undervaluation — mixed insider signal that warrants attention
Texas/Colorado RM hiring expansion is an optionality story with no track record yet; $1B pipeline (up from $800M) is nascent and could face execution risk, competitive response, or regional economic headwinds
Revenue normalization in Q1 2026 (-7% YoY) combined with expense guidance of +4% for 2026 creates operating leverage risk if loan growth disappoints — the efficiency ratio below 50% may not hold if top-line fades
NIM guidance range of 380-390 bps is wide and assumes rate stability; any 50-75 bps of additional Fed cuts could push deposit betas higher and compress organic NIM toward 350 bps, which would substantially impair earnings power
No credit-cycle stress test data visible in fact base: NCOs at 9-11 bps appear benign but reflect a post-COVID normalization environment; provision at $6.6M seems light for a $67B asset bank if macro deteriorates

Seth Klarman — 🟡 watch · 48/100 · medium confidence

SouthState Bank Corp (SSB) is a legitimate value candidate for examination but fails to clear the Klarman margin-of-safety bar at current prices. The stock trades at ~1.09x tangible book value ($101.37 against estimated TBV near $92–93/share implied by $9.059B equity and ~98M shares, though goodwill/intangibles from the Independent Financial acquisition inflate GAAP equity, making hard TBV closer to $75–85/share — exact figure not confirmed in excerpts). The P/E of 12.4x on reported net income of $799M is superficially cheap, but critically, much of that net income is driven by purchase accounting accretion (~$260M remaining) which is a wasting, non-recurring asset — not sustainable normalized earnings power. The true normalized earning power ex-accretion is materially lower and cannot be precisely quantified from available disclosures. The valuation block correctly notes FCF-based DCF is inappropriate for banks; the proper frame is P/TBV vs. ROE. ROE of 8.82% against a cost of equity likely 9–11% for a regional bank implies the bank is marginally value-creative at best, which does not support a premium to TBV. Price-to-FCF of 42.94x is essentially meaningless for a bank but signals operating cash flow ($300M) is far below reported net income ($799M), raising questions about earnings quality that a conservative analyst must weigh. On the asset-value dimension: total assets of $67.2B against total liabilities of $58.1B yields $9.1B in book equity, but bank assets are not liquidation assets — loan books carry credit risk, held-to-maturity securities may have unrealized losses, and goodwill/intangibles from two large acquisitions (CenterState 2020, Independent Financial 2025) are likely material. No hard TBV or intangibles breakdown is available in the excerpts, a data gap that prevents a confident margin-of-safety assessment. The bear case centers on accretion exhaustion: when the $260M remaining loan discount accretes through (12–18 months), EPS falls materially unless organic loan growth and NIM expansion compensate. NIM ex-accretion was essentially flat in Q4 2025, organic NIM improvement is not demonstrated, and management's 2026 NIM guidance of 380–390 bps is wide and rate-dependent. Expense guidance of +4% on a $1.4B NIE base adds ~$56M in annual costs with no matching revenue commitment. Q1 2026 revenue already missed YoY by 7%. On the positive side: loan/deposit growth of 8% annualized is real, capital ratios are solid (CET1 11.4%, TCE 8.8%), management executed the Independent Financial integration credibly, credit metrics are pristine (NCOs 9–11 bps), and the Texas/Colorado expansion provides a longer-term organic growth option. Management's Q4 buyback at $90.65 average (2% of shares) signals insider conviction. Analyst targets of $115–125 from JPMorgan and Barclays suggest ~15–25% upside from current levels. However, from a strict Klarman framework: there is no evident forced selling or orphaned security dynamic here; the stock is NYSE-listed, analyst-covered, and fairly well-understood. The accretion complexity is real but not deeply misunderstood by the market — it's widely discussed in earnings calls. The price is not demonstrably below conservative intrinsic value with a wide margin of safety; at best it is fairly priced to modestly cheap relative to normalized earnings power. The downside scenario (accretion exhaustion, rate cuts compressing NIM, expense growth exceeding revenue, credit normalization) could push EPS toward $6–7 range on a normalized basis, implying a fair value of $70–84 at 11–12x normalized P/E, versus the current $101 — suggesting limited margin of safety and potential 15–30% downside in the bear case. This is not the asymmetric, downside-protected payoff Klarman demands. I hold a watch stance: the situation deserves monitoring — if the stock were to trade to $80–85 (closer to hard TBV and ~11x normalized earnings), the margin of safety would become compelling. At $101, the entry is premature by Klarman standards.

Key points

P/TBV of ~1.09x on GAAP book overstates asset coverage because goodwill/intangibles from two large acquisitions (CenterState 2020, Independent Financial 2025) inflate book; hard TBV likely materially lower — not confirmed in filings excerpts
Reported net income ($799M, P/E 12.4x) is heavily distorted by ~$260M remaining purchase accounting accretion — a wasting, non-cash, non-recurring benefit; normalized EPS without accretion is materially lower and unquantified
ROE of 8.82% barely clears or falls short of cost of equity for a regional bank, implying the franchise is value-neutral to slightly value-destructive at current TBV multiples — no premium warranted
8% annualized loan and deposit growth, pristine credit (NCOs 9–11 bps), CET1 of 11.4% are genuine positives; Texas/Colorado expansion via $5B pipeline and 26 RM hires adds organic growth optionality
Management conviction expressed via Q4 buyback at $90.65 average (2% of float); JPMorgan Overweight target $115, Barclays Overweight target $122 suggest institutional upside consensus
Efficiency ratio below 50% and NIM at 386 bps (tax-equiv.) are strong operational metrics, but NIM ex-accretion flat-to-up only 2 bps in Q4 — organic margin pressure is real
No identifiable forced-seller dynamic, orphaned-security structure, or deep complexity discount that would create a Klarman-style mispricing opportunity separate from general market valuation

Red flags

Accretion cliff: $260M remaining purchase accounting income will exhaust in 12–18 months; without organic NIM expansion or loan growth acceleration, EPS could drop 20–35% from current levels on a normalized basis
Q1 2026 revenue missed YoY by 7% despite loan growth — early signal that accretion normalization is already compressing reported results faster than organic growth compensates
Operating cash flow ($301M) dramatically below net income ($799M), a 2.7x gap that raises earnings quality concerns typical of heavy acquisition accounting; price-to-FCF of 42.94x on this basis is extremely elevated
Hard tangible book value not determinable from available excerpts due to undisclosed goodwill/intangibles from two acquisitions — the 'downside floor' is unverifiable, a critical gap for a downside-first investor
Expense guidance +4% on $1.4B base ($56M incremental) with RM hiring and Texas/Colorado build-out adds fixed cost risk if revenue normalization continues; efficiency ratio could deteriorate meaningfully
No catalyst or structural mispricing identified — the situation is well-covered by sell-side (JPM, Barclays, Raymond James, Zacks), limiting the 'orphaned/overlooked' premium that Klarman situations typically require
Director David Brooks sold $1.41M in stock (Apr 2026) while another director received stock compensation — mixed insider signal; not alarming but not a strong alignment indicator
Macro sensitivity: NIM guidance 380–390 bps assumes rate stability; any Fed rate cuts or deposit beta acceleration could compress margins and invalidate the earnings thesis, with no disclosed stress-test scenarios

Walter Schloss — 🟡 watch · 48/100 · medium confidence

SouthState Bank Corp (SSB) presents a mixed picture through the Schloss lens. On the positive side, it trades at only 1.09x price-to-book ($9.06B equity vs ~$9.9B market cap), which is close to — though not below — book value, the kind of territory Schloss found interesting. The balance sheet shows minimal long-term debt ($55M reported, though this figure appears to reference an older period given the bank's current $67B asset base). Net income is solid at $798M and ROE is 8.8%. However, the Schloss framework struggles here for several structural reasons: (1) Bank balance sheets are inherently highly leveraged — $67B assets against $9B equity means ~7:1 leverage, which Schloss would view with serious concern even though it's normal for banking; (2) the price is AT the 52-week high ($101.37), the precise opposite of the beaten-down, out-of-favor securities Schloss sought; (3) much of the apparent earnings strength is purchase accounting accretion from the Independent Financial acquisition, not clean organic asset value — Schloss distrusted complex accounting; (4) there is meaningful goodwill/intangibles embedded in the $9B book value from acquisitions, reducing tangible book below stated book (price-to-tangible-book likely higher than 1.09x); (5) a director sold $1.41M in stock in April 2026, a mild negative signal. The Q1 2026 revenue miss (-7% YoY) and accretion dependency add opacity. The bank is not cheap enough, not beaten-down enough, and too complex for Schloss's simple-balance-sheet bargain shop approach.

Key points

Price-to-book of 1.09x is near book but not a deep discount; Schloss preferred materially below book
Stock is AT 52-week high — Schloss bought beaten-down securities, not ones near peaks
ROE of 8.8% is modest, suggesting book value is not being compounded aggressively
Low reported long-term debt figure ($55M) appears stale/inapplicable to current bank structure; inherent banking leverage (~7:1 assets/equity) conflicts with Schloss low-debt preference
Q4 2025 EPS growth and NIM of 386bps indicate a functioning bank, not a distressed one requiring deep-value rescue
Minimal long-term debt in the traditional sense (non-deposit) suggests some balance sheet conservatism
Dividend paid and 11% dividend raise signals capital return to shareholders

Red flags

Stock trading at 52-week high — exact opposite of Schloss's beaten-down bargain requirement
Purchase accounting accretion ($260M remaining) creates complex, opaque earnings quality that Schloss would distrust
Director David Brooks sold $1.41M in stock in April 2026 — insider selling is a negative signal
Goodwill and intangibles from acquisitions likely reduce tangible book value below stated book, worsening the P/TBV ratio
$67B asset base with inherent banking leverage does not fit Schloss's preference for conservatively financed, low-debt companies
Revenue missed estimates in Q1 2026 (-7% YoY) while EPS beat on accounting items — underlying organic quality unclear
Texas/Colorado expansion thesis requires execution on narrative/growth, not verifiable hard asset value — not a Schloss-style catalyst
Complexity of acquisition integration, PCD loan rotations, and correspondent capital markets income make filings hard to read at face value

Chuck Akre — abstained

SouthState Bank Corporation is a commercial bank — precisely the category I explicitly exclude from this framework. Banks are balance-sheet-intensive, highly leveraged by design (total liabilities $58.1B vs. equity $9.1B, ~6.4x leverage), and their 'returns' are inseparable from that leverage. ROE of 8.8% is not a signal of genuine business economics but an artifact of a leveraged intermediary with thin spread income. The three-legged stool cannot be evaluated meaningfully here: 'capital-light franchise with pricing power' does not describe a bank whose assets are loans and whose liabilities are deposits. FCF-based compounding analysis is inapplicable (the DCF block itself flags this). I cannot distinguish between leverage-driven ROE inflation and genuine franchise returns. The reinvestment runway question becomes 'can they grow the loan book?' — which is not the compounding dynamic I look for. Integrity and management quality could be assessed qualitatively, but without the fundamental economic engine fitting my framework, a verdict would be intellectually dishonest. I abstain.

Key points

Banking is explicitly outside my applicable universe — balance-sheet-driven, leveraged intermediary model
ROE of 8.8% is modest and inseparable from ~6.4x asset-to-equity leverage by design
No 'capital-light franchise' characteristic — the business model is capital IS the product
FCF-per-share compounding framework inapplicable to bank economics
Cannot assess reinvestment runway meaningfully — loan book growth is not the same as reinvesting FCF at high ROIC
Valuation system (DCF) also flagged not applicable for same structural reason

Red flags

Leverage ratio (~6.4x) would be disqualifying in any non-bank context as financial engineering
ROE 8.8% well below my 20%+ threshold, though this is structural not a red flag per se
Purchase accounting accretion inflating near-term EPS — precisely the kind of non-cash, non-recurring accounting complexity I distrust
$9B+ acquisition integration risk introduces execution uncertainty inconsistent with predictable compounding

Philip Fisher — abstained

SouthState Bank Corporation is a regional banking institution. My investment criteria are built entirely around companies with durable organic growth driven by R&D, new products, proprietary technology, or expanding addressable markets — the kind of compounding franchise I identified in Motorola or Texas Instruments. Banking is fundamentally a spread-lending, deposit-gathering commodity business where growth is largely cyclical, acquisition-driven, or macro-rate-dependent, not product-innovation-driven. SSB's revenue growth in 2025 (+52% YoY) is almost entirely the result of the Independent Financial Corp acquisition, not organic product or market expansion. The 8% loan/deposit growth is respectable for a bank but does not represent the kind of above-industry, volume-driven, product-led growth my framework requires. There is no R&D spending to evaluate, no product pipeline, no proprietary technology moat, and no scuttlebutt methodology applicable to assess competitive differentiation in a commodity lending market. The company competes on geography, relationship banking, and spread management — none of which constitute the durable, widening competitive advantages I look for. Applying my criteria here would be a category error.

Key points

Revenue growth of 52% YoY in Q4 2025 is acquisition-driven (Independent Financial Corp), not organic product-led growth — fails my core criterion
No R&D investment or product pipeline exists; banking is a spread business with no technology or innovation moat to evaluate
8% organic loan/deposit growth is cyclical/rate-environment-dependent, not evidence of a durable franchise expansion
Business model (NIM, deposit gathering, credit underwriting) is fundamentally a commodity with limited pricing power or differentiation
My scuttlebutt method has no meaningful application here — no customers evaluating a proprietary product, no suppliers, no technology ecosystem to probe

Red flags

Growth is bought via acquisition (IFC deal), not earned through new products or markets — my primary red flag
Accretion-dependent EPS (~$260M remaining) masks true organic earnings power, obscuring management quality signals
No R&D investment means no future product pipeline — the business cannot compound via reinvestment into innovation
Commodity banking competition in Southeast/Texas markets offers no defensible moat analogous to what I require

Joel Greenblatt — abstained

SouthState Bank Corporation is a commercial bank — precisely the sector Greenblatt explicitly excludes from the Magic Formula framework. For banks and other financial intermediaries, EBIT is not a meaningful concept (interest expense is an operating cost, not a financing cost), invested capital cannot be reliably decomposed into net working capital plus net fixed assets, and enterprise value is distorted because debt (deposits) is raw material rather than leverage. The two core Magic Formula inputs — EBIT/Invested Capital (ROIC) and EBIT/EV (earnings yield) — are simply not calculable in any trustworthy way for a bank. The valuation block in the fact base itself flags DCF as not applicable for the same structural reason. This is not a close call; Greenblatt himself explicitly stated financials and utilities should be excluded from the formula because the capital structure makes the inputs meaningless. Attempting to force a verdict here would require inventing proxies that Greenblatt never endorses and would produce an unreliable score.

Key points

Banking sector is explicitly excluded from Greenblatt's Magic Formula and ROIC-based framework
EBIT is not separable from interest income/expense in a bank's income statement — net interest income IS the operating line, not a residual after financing costs
Invested capital denominator (NWC + net fixed assets) is meaningless for a bank whose 'capital' is overwhelmingly deposit liabilities funding loan assets
Enterprise Value calculation is distorted — $58B in liabilities are largely customer deposits (operating inputs), not financial leverage in the corporate sense
No special-situation angle is clearly present: the Independent Financial acquisition is largely integrated per management, reducing any spinoff/restructuring mispricing opportunity
ROE of 8.8% and P/B of 1.09x are the appropriate banking metrics but fall outside Greenblatt's analytical toolkit

Red flags

Financials sector — fundamental incompatibility with Magic Formula inputs EBIT/IC and EBIT/EV
Cannot derive a reliable EBIT figure: net interest income, provision expense, and non-interest income are intertwined with balance sheet leverage in ways that make operating earnings ambiguous
Capital base indeterminate: total assets of $67B vs. stockholders' equity of $9B reflects bank leverage structure, not industrial capital employed
Attempting to apply the framework here would require ad hoc adjustments Greenblatt never sanctions, producing a false precision score

Bruce Greenwald — abstained

SouthState Bank Corporation (SSB) is a commercial bank, and my EPV/asset-reproduction framework does not cleanly apply to financial intermediaries. Banks are fundamentally leveraged balance-sheet businesses where (1) 'earnings power' is inseparable from credit risk and leverage embedded in assets (~$67B total assets against ~$9B equity), (2) reproduction value of assets cannot be estimated the way it can for an industrial company — deposits, loan books, and regulatory capital are the 'assets' and their reproduction cost is not comparable to plant/equipment/brand reconstruction, and (3) the FCF-based and NOPAT-based capitalization that underpins EPV is rendered meaningless because bank operating cash flow reflects changes in loan originations, deposit flows, and securities portfolios rather than true distributable operating earnings. The valuation block itself flags DCF as not applicable for this reason. The correct metrics for banks are P/B vs. ROE vs. cost of equity, NIM sustainability, credit quality, and capital adequacy — none of which are my primary analytical tools. Forcing EPV onto SSB would produce numbers that are epistemically misleading. I therefore abstain rather than stretch the framework.

Key points

Banking sector is explicitly outside the scope of my EPV/asset-reproduction methodology — the valuation block confirms DCF not applicable
Total assets of $67B vs. $9B equity means leverage is the primary value driver, not operating earnings power in the industrial sense
Deposit franchises and loan books cannot be valued via asset reproduction cost the way factories, brands, or distribution networks can
Net income of $799M is heavily influenced by acquisition accretion (~$260M remaining), NIM spreads on leveraged balance sheet, and credit assumptions — normalizing to a sustainable NOPAT is not credible without deep credit cycle analysis
ROE of 8.8% vs. price-to-book of 1.09x is the correct framing for this name, but that is a bank analyst's P/B vs. COE spread analysis, not Greenwald EPV

Red flags

Applying EPV capitalization to a bank's reported net income would conflate leverage-amplified spread income with true operating earnings power — a category error
Purchase accounting accretion inflates current earnings, making normalization across the cycle especially unreliable for EPV purposes
Abstaining is the intellectually honest response; any score I assigned would be false precision

Terry Smith (Fundsmith) — abstained

SouthState Bank Corp is a commercial bank — precisely the type of capital-intensive, leveraged, cyclical financial institution that Fundsmith explicitly excludes from its investment universe. Terry Smith has consistently and publicly stated that banks are uninvestable through his quality lens because: (1) they are inherently highly leveraged institutions (total liabilities $58.1B vs. equity $9.1B — a leverage ratio of ~6.4x), making ROE a deeply distorted measure of underlying returns; (2) ROCE in the Fundsmith sense is not calculable or meaningful for a bank — the 'capital employed' concept collapses when the business model IS lending other people's money at a spread; (3) asset-intensity is extreme and intrinsic — the entire balance sheet ($67.2B in assets) is the product; (4) earnings quality is opaque, with large purchase accounting accretion (~$260M remaining from Independent Financial acquisition) inflating reported EPS in ways that obscure organic profitability; (5) the business is acquisition-driven (serial M&A roll-up via Independent Financial $11B+ deal), which Smith explicitly distrusts; and (6) demand is cyclically sensitive to interest rates, credit cycles, and macro conditions — the opposite of the resilient, repeat-purchase demand Smith seeks. The FCF-based DCF is itself flagged not-applicable by the valuation module, consistent with this assessment. There is simply no basis to apply the Fundsmith quality screen here.

Key points

Banking is explicitly excluded from the Fundsmith investable universe — Smith has publicly stated he does not own banks
Leverage ratio of ~6.4x (liabilities/equity) makes balance sheet fundamentally incompatible with Smith's low-leverage requirement
ROCE cannot be meaningfully applied to a bank — the entire asset base is the business model, not capital employed in the traditional sense
ROE of 8.8% is well below the 20%+ ROCE Smith requires, and even this is distorted by acquisition accretion
Serial M&A (Independent Financial acquisition, prior roll-up history) is a core Fundsmith red flag
Purchase accounting accretion ($260M remaining) inflates EPS, reducing earnings quality and transparency
Capital intensity is intrinsic — the bank cannot grow without growing its balance sheet
No recurring, asset-light, pricing-power-driven revenue stream of the type Fundsmith prizes

Red flags

Extreme financial leverage (~6.4x liabilities/equity) — disqualifying under Smith criteria
Bank business model is inherently capital-intensive with thin, rate-sensitive spreads
Serial acquisitive growth strategy (Independent Financial deal) with large goodwill and merger-adjusted earnings
Reported EPS heavily dependent on non-cash purchase accounting accretion — weak earnings quality
No durable economic moat of the brand/network/switching-cost variety Smith identifies
Revenue down 7% YoY in Q1 2026 despite earnings beat — highlights accretion-driven, not organic, profitability
Operating cash flow ($300.8M) materially below net income ($798.7M) — poor cash conversion signal

Fact base appendix

Price

last_close: 101.37
as_of: 2026-06-27
high_52w: 101.37
low_52w: 101.37
pct_below_52w_high: 0.0

Fundamentals

last_price: 101.37
market_cap: 9900609396
fifty_two_week_high: 108.46
fifty_two_week_low: 84.48
beta: 0.7003136
currency: USD
exchange: NEW YORK STOCK EXCHANGE, INC.
sector: Banking
industry: Banking
price_source: finnhub
bars: 1
entity: SOUTHSTATE BANK CORP
fiscal_year: None
net_income: 798667000
net_income_period: 2025-12-31
operating_cash_flow: 300846000
operating_cash_flow_period: 2025-12-31
capex: 70255000
capex_period: 2025-12-31
total_assets: 67197412000
total_assets_period: 2025-12-31
total_liabilities: 58138304000
total_liabilities_period: 2025-12-31
stockholders_equity: 9059108000
stockholders_equity_period: 2025-12-31
cash_and_equivalents: 377627000
cash_and_equivalents_period: 2017-12-31
long_term_debt: 55358000
long_term_debt_period: 2016-12-31
shares_outstanding: 98068647
roe: 0.0882
debt_to_equity: 0.0061
current_ratio: None
free_cash_flow: 230591000
pe_ratio: 12.4
price_to_fcf: 42.94
fundamentals_source: edgar_companyfacts
price_to_book: 1.09

Filings reviewed

10-Q (2026-05-01) https://www.sec.gov/Archives/edgar/data/764038/000110465926053548/ssb-20260331x10q.htm
8-K (2026-04-23) https://www.sec.gov/Archives/edgar/data/764038/000110465926047690/ssb-20260423x8k.htm
8-K (2026-04-15) https://www.sec.gov/Archives/edgar/data/764038/000110465926043739/ssb-20260415x8k.htm
10-K (2026-02-20) https://www.sec.gov/Archives/edgar/data/764038/000110465926017884/ssb-20251231x10k.htm
10-Q (2025-10-31) https://www.sec.gov/Archives/edgar/data/764038/000110465925104685/ssb-20250930x10q.htm
10-K (2025-02-21) https://www.sec.gov/Archives/edgar/data/764038/000155837025001274/ssb-20241231x10k.htm

Other sources

[news] SSB Stock Price and Chart — NYSE:SSB - TradingView
[news] These banks might be next to pair up, says analyst who called the $11 billion Comerica sale - MarketWatch
[news] SouthState Bank Corp (SSB) director awarded 506 shares in lieu of cash retainer - Stock Titan
[news] SouthState Bank Corp ($SSB) CEO 2025 Pay Revealed - Quiver Quantitative
[news] SouthState 2026: $2.57B in community loans, 1.7M gallons of water saved - Stock Titan
[news] SouthState Bank director David Brooks sells $1.41 million in stock - Investing.com
[news] SouthState Bank Corp (SSB) Q3 2025 Earnings Call Highlights: Robust EPS Growth and Strategic ... - Yahoo Finance
[news] SouthState Bank Corp (NYSE:SSB) Q1 Earnings: Revenue Misses Estimates, EPS Beats Expectations - ChartMill
[news] SouthState Bank Corp completes redomicile to Florida and assumes obligations - Investing.com
[news] SouthState Bank Corp Buys 8,029 Shares of GE Aerospace $GE - MarketBeat
[news] SouthState Bank (SSB) Stock Price, News & Analysis $SSB - MarketBeat
[news] SouthState Bank Q1 Earnings Call Highlights - Yahoo Finance
[news] A Dewall Waters Net Worth (2026) - GuruFocus
[news] SouthState Bank Corp (SSB) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Strategic ... - Yahoo Finance
[news] SouthState Bank Corp SEC 10-K Report - TradingView
[discussion] $SSB Price: $93.68 (-0.22%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.62% RSI:
[discussion] $SSB Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $2.29 up 160.23% YoY • Reported

[discussion] $SSB Share Price: $97.06

Contract Selected: Dec 18, 2026 $85 Calls

Buy Zone: $13.26 – $16.38 Targe

[discussion] Raymond James identified ten banks that could benefit if the Federal Reserve delivers fewer rate cut
[discussion] $SSB $588 on $SPY. That's the number. That's the level. It always bounces there. Always. 1
[discussion] $SSB Daily Renko

The Green Brick was not completed on Friday.

If it gets completed on Tuesday

[discussion] $SSB Share Price: $106.49

Contract Selected: Sep 18, 2026 $100 Calls

Buy Zone: $7.65 – $9.45 Targe

[earnings_call] SouthState Bank Corporation SSB Q4 2025 Earnings Call
[discussion] $SSB Q4 earnings beat — but not all green lights.

EPS jumped 28% YoY, driven by surging NII and gro

[discussion] $SSB shatters earnings expectations — is this a sign of more gains ahead? 🚀

SouthState's Q4 EPS

[discussion] $SSB Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $2.48 up 31.22% YoY • Reported

[discussion] $SSB Current Stock Price: $98.42 Contracts to trade: $100 SSB Feb 20 2026 Call Entry: $1.98 Exit: $2
[discussion] Barclays updates rating for SouthState Bank ( $SSB ) to Overweight, target set at 125 → 122.
[discussion] JP Morgan has updated their rating for SouthState Bank ( $SSB ) to Overweight with a price target of
[discussion] $SSB Current Stock Price: $92.80 Contracts to trade: $95 SSB Dec 19 2025 Call Entry: $0.40 Exit: $0.
[discussion] Barclays updates rating for SouthState Bank ( $SSB ) to Overweight, target set at 128 → 125.

Generated 2026-07-17T20:51:13 · est. cost $2.27

What each investor thinks

AI & Disruption Referee (Christensen-style) Referee

pass · 72

Warren Buffett Quality

watch · 58

Valuation Referee (Damodaran-style) Referee

watch · 55

Benjamin Graham Value

watch · 55

Ray Dalio Risk

watch · 52

Stanley Druckenmiller Risk

watch · 52

Peter Lynch Growth

watch · 52

Howard Marks Risk

watch · 52

Charlie Munger Quality

watch · 52

Forensic Short-Seller (Chanos/Einhorn-style) Referee

watch · 52

Michael Mauboussin Quality

watch · 52

Seth Klarman Value

watch · 48

Walter Schloss Value

watch · 48

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →